Journal article
Bacillus Calmette-Guérin Failures and Beyond: Contemporary Management of Non-Muscle-Invasive Bladder Cancer
Reviews in urology, Vol.10(4), pp.281-289
2008
PMCID: PMC2615101
PMID: 19145271
Abstract
In the United States, bacillus Calmette-Guérin (BCG) is the treatment most used for superficial bladder cancer. Patients with carcinoma in situ (CIS) treated with intravesical BCG plus interferon have a 60% to 70% chance of a complete and durable response if they were never treated with BCG or if they failed only 1 prior induction or relapsed more than a year from induction. Intravesical gemcitabine is safe, but its usefulness for BCG-refractory patients is unclear. Valrubicin, approved for intravesical treatment of BCG-refractory CIS of the bladder, has efficacy and acceptable toxicity. Cystectomy should be considered in high-risk, non-muscle-invasive cancer, particularly if intravesical therapy failed.
Details
- Title: Subtitle
- Bacillus Calmette-Guérin Failures and Beyond: Contemporary Management of Non-Muscle-Invasive Bladder Cancer
- Creators
- H. Barton GrossmanMichael A O’DonnellMichael S CooksonRichard E GreenbergThomas E Keane
- Resource Type
- Journal article
- Publication Details
- Reviews in urology, Vol.10(4), pp.281-289
- Publisher
- MedReviews, LLC
- PMID
- 19145271
- PMCID
- PMC2615101
- ISSN
- 1523-6161
- eISSN
- 2153-8182
- Language
- English
- Date published
- 2008
- Academic Unit
- Urology
- Record Identifier
- 9984051734002771
Metrics
36 Record Views